Parkinson Disease
Conditions
Brief summary
To assess the predictive value of sequential administration of WHO-5 and MDI (Major Depression Inventory) for the clinical management of Parkinson Disease (PD) patients by * determination of the prevalence of depression in PD patients, based on MDI severity categories and the self-rating scale WHO-5, where poor well being was indicated. * exploration of influencing factors (PD status, therapeutic status) on the prevalence of MDI depression categories.
Interventions
None listed
Sponsors
Boehringer Ingelheim
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
30 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. PD patients attending one of the participating neurologist practices during 2 fixed weeks in November 2008 2. Idiopathic PD with or without fluctuations 3. Male or female PD patients aged at least 30 4. Ability to reliably complete self-rating scales (WHO-5, MDI) ), according to the physician's judgement. 5. Written informed consent by the patient for study participation.
Exclusion criteria
1. PD Patients who only attend the practice to get a prescription and are not seen by the doctor on that day 2. Patients who are not able to understand the questionnaires (e.g. due to mental impairment or language problems).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Prevalence of patients with depressive symptoms (based on WHO-5 and MDI) in total and in subgroups | day 1 |
Secondary
| Measure | Time frame |
|---|---|
| MDI score (for a subgroup of patients with WHO-5 score < 13 or any WHO-5 item rated with 0 or 1) | day 1 |
| WHO-5 score and items | day 1 |
| Correlation of WHO-5 and MDI (for a subgroup of patients with a WHO-5 score < 13 or any WHO-5 item rated with 0 or 1) in PD patients | day 1 |
| Investigator assessment of the applicability of the WHO-5 for screening for depression in PD patients | day 1 |
Countries
Germany
Outcome results
None listed